194 related articles for article (PubMed ID: 27020582)
1. Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer.
Conteduca V; Crabb SJ; Scarpi E; Hanna C; Maines F; Joyce H; Fabbri P; Derosa L; Massari F; Lolli C; Zarif S; Jones RJ; Caffo O; Elliott T; De Giorgi U
Mol Diagn Ther; 2016 Jun; 20(3):255-63. PubMed ID: 27020582
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
Armstrong AJ; Saad F; Phung D; Dmuchowski C; Shore ND; Fizazi K; Hirmand M; Forer D; Scher HI; Bono J
Cancer; 2017 Jun; 123(12):2303-2311. PubMed ID: 28171710
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
[TBL] [Abstract][Full Text] [Related]
4. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
[TBL] [Abstract][Full Text] [Related]
5. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN
N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494
[TBL] [Abstract][Full Text] [Related]
6. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
[TBL] [Abstract][Full Text] [Related]
7. Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer.
Kato H; Furuya Y; Miyazawa Y; Miyao T; Syuto T; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2016 Nov; 36(11):6141-6149. PubMed ID: 27793943
[TBL] [Abstract][Full Text] [Related]
8. (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
De Giorgi U; Caroli P; Scarpi E; Conteduca V; Burgio SL; Menna C; Moretti A; Galassi R; Rossi L; Amadori D; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1276-83. PubMed ID: 25808631
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
10. Is there an antiandrogen withdrawal syndrome with enzalutamide?
Rodriguez-Vida A; Bianchini D; Van Hemelrijck M; Hughes S; Malik Z; Powles T; Bahl A; Rudman S; Payne H; de Bono J; Chowdhury S
BJU Int; 2015 Mar; 115(3):373-80. PubMed ID: 24906049
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.
Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527
[TBL] [Abstract][Full Text] [Related]
12. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
Iguchi T; Tamada S; Kato M; Yasuda S; Otoshi T; Hamada K; Yamasaki T; Nakatani T
Int J Clin Oncol; 2019 Jul; 24(7):848-856. PubMed ID: 30741370
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
Rescigno P; Lorente D; Bianchini D; Ferraldeschi R; Kolinsky MP; Sideris S; Zafeiriou Z; Sumanasuriya S; Smith AD; Mehra N; Jayaram A; Perez-Lopez R; Mateo J; Parker C; Dearnaley DP; Tunariu N; Reid A; Attard G; de Bono JS
Eur Urol; 2016 Nov; 70(5):724-731. PubMed ID: 26965561
[TBL] [Abstract][Full Text] [Related]
16. Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.
Conteduca V; Crabb SJ; Jones RJ; Caffo O; Elliott T; Scarpi E; Fabbri P; Derosa L; Massari F; Numico G; Zarif S; Hanna C; Maines F; Joyce H; Lolli C; De Giorgi U
PLoS One; 2016; 11(7):e0158952. PubMed ID: 27434372
[TBL] [Abstract][Full Text] [Related]
17. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.
Rescigno P; Dolling D; Conteduca V; Rediti M; Bianchini D; Lolli C; Ong M; Li H; Omlin AG; Schmid S; Caffo O; Zivi A; Pezaro CJ; Morley C; Olmos D; Romero-Laorden N; Castro E; Saez MI; Mehra N; Smeenk S; Sideris S; Gil T; Banks P; Sandhu SK; Sternberg CN; De Giorgi U; De Bono JS
Eur Urol Oncol; 2020 Apr; 3(2):176-182. PubMed ID: 31307958
[TBL] [Abstract][Full Text] [Related]
18. Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide.
Takemura K; Ito M; Nakanishi Y; Kataoka M; Sakamoto K; Suzuki H; Tobisu KI; Koga F
Anticancer Res; 2019 Oct; 39(10):5773-5780. PubMed ID: 31570481
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
[TBL] [Abstract][Full Text] [Related]
20. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
